Dipiaron LLC

Dipiaron LLC is an innovative biotech start-up company, a participant of the Skolkovo project

Our project is aimed at creating a new original drug for the treatment of type 2 diabetes mellitus, metabolic syndrome and obesity.
The drug production technology has been developed, preclinical trials have been successfully carried out.
Thanks to venture investment from the PharmMed Innovations fund managed by Unicorn Capital Partners LLC, we have begun the next stage of project development - clinical trials
Our principles
New milestones based on compelling evidence
Compliance with current research requirements at every stage of development and production
Further development
Exploring opportunities for expanding applications and new combinations
Olga Golub
Ivan Tyurenkov
Director of Science
Daniil Nemenov
Clinical development consultant
Our site uses cookies, by staying on the page you agree to their use